glp-1 nejm Orforglipron, an Oral Small-Molecule Receptor Agonist, in Early Type 2 Diabetes NEJM Clinician: Should we hold

Understanding the difference helps you choose an evidence-based approach to weight management

It seems like Eli Lilly is poised to dominate once Retatrutide gets approved (and chinese "research chemical" factories will win either way.) So, does Eli Lilly = ASU frat leader?

A Smarter, Gentler Way to Support Metabolic, Brain, and Gut HealthGLP-1 (glucagon-like peptide-1) has become one of the most talked-about molecules in modernmedicine

The odds ratio of different GLP-1 agonists are combined via a random effects model

We accept insurance and have self-pay options available.

The 2025 Nobel Prize in Physiology or Medicine is awarded to Joel Habener, Svetlana Mojsov, and Jens Juul Holst for their discovery and development of GLP-1based therapeutics, which have revolutionized the treatment of diabetes and obesity worldwide. | 29 comments on LinkedIn